Adding Ivosidenib to Help Patients With Advanced Chondrosarcoma
Recruiting · Phase 3 · Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen · 19 states
This study looks at how well a medicine called ivosidenib works for patients with locally advanced or metastatic chondrosarcoma that has a specific gene change called an IDH1 mutation. The goal is to see if this treatment can help patients who have not received extensive treatment or who have only had one treatment before. Researchers will check how long patients can stay without their cancer getting worse while taking this medicine compared to a placebo, which is a look-alike pill with no medicine in it.
The trial's ID number is NCT06127407. This is a Phase 3 study, which means it is looking closely at how well the treatment works and how safe it is. The study plans to include about 136 participants and is regulated by the FDA.
Who can join
Adults aged 18 and older can join this trial if they have a specific type of chondrosarcoma that has an IDH1 mutation. They must have at least one measurable tumor and can have had one previous treatment. Those who are pregnant, have certain heart issues, or cannot take pills are not able to participate. The trial team will confirm eligibility for each person.
Condition
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will take ivosidenib, a pill taken once a day, and the other group will take a placebo, which looks the same but has no active medicine. Everyone will take their assigned treatment until their condition changes or they decide to stop. The expected treatment duration is about two years.
Where
This trial is enrolling at 22 locations. Recruiting sites are listed first.
Cleveland Clinic
Cleveland, Ohio
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts
Recruiting
Duke University
Durham, North Carolina
Recruiting
Emory Winship Cancer Institute
Atlanta, Georgia
Recruiting
Johns Hopkins University
Baltimore, Maryland
Recruiting
Mayo Clinic - Jacksonville, Fl
Jacksonville, Florida
Recruiting
Mayo Clinic - Rochester, Mn
Rochester, Minnesota
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York
Recruiting
Study contact
Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
Developed a radiotherapy technique for patients with soft tissue and bone sarcomas who cannot have surgery. Treats sarcoma, bone cancer and soft tissue sarcoma.
Melanoma surgeon and immunotherapy researcher, MSK. Treats melanoma, sarcoma and merkel cell carcinoma. Offers immunotherapy and early drug development.